EcoDrugPlus

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSNFUG00015015285
Gene Symbol: MTOR
1 Cross references
216 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSNFUG00015001733
Gene Symbol: MC1R
3 Cross references
159 Possible Orthologues:

Melanocortin Receptor 4-Like

Ensembl ID : ENSNFUG00015019369
Gene Symbol: LOC107383086
3 Cross references
89 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSNFUG00015021915
Gene Symbol: MTNR1AA
1 Cross references
186 Possible Orthologues:

Membrane Metalloendopeptidase

Ensembl ID : ENSNFUG00015000649
Gene Symbol: MME
3 Cross references
233 Possible Orthologues:

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSNFUG00015007043
Gene Symbol: LOC107385191
3 Cross references
206 Possible Orthologues:

Metabotropic Glutamate Receptor 3-Like

Ensembl ID : ENSNFUG00015018300
Gene Symbol: LOC107388863
3 Cross references
215 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSNFUG00015018769
Gene Symbol: LOC107386961
3 Cross references
211 Possible Orthologues:

Methionyl Aminopeptidase 2b

Ensembl ID : ENSNFUG00015010243
Gene Symbol: METAP2B
1 Cross references
220 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSNFUG00015005761
Gene Symbol: LOC107386038
3 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSNFUG00015001405
Gene Symbol: LOC107376681
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSNFUG00015002440
Gene Symbol: MAPK10
1 Cross references
88 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).